Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 310

1.

Choosing the right strategy based on individualized treatment effect predictions: combination versus sequential chemotherapy in patients with metastatic colorectal cancer.

Kwakman JJM, van Kruijsdijk RCM, Elias SG, Seymour MT, Meade AM, Visseren FLJ, Punt CJA, Koopman M.

Acta Oncol. 2019 Jan 18:1-8. doi: 10.1080/0284186X.2018.1564840. [Epub ahead of print]

PMID:
30657353
2.

Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium.

Chang AR, Grams ME, Ballew SH, Bilo H, Correa A, Evans M, Gutierrez OM, Hosseinpanah F, Iseki K, Kenealy T, Klein B, Kronenberg F, Lee BJ, Li Y, Miura K, Navaneethan SD, Roderick PJ, Valdivielso JM, Visseren FLJ, Zhang L, Gansevoort RT, Hallan SI, Levey AS, Matsushita K, Shalev V, Woodward M; CKD Prognosis Consortium (CKD-PC).

BMJ. 2019 Jan 10;364:k5301. doi: 10.1136/bmj.k5301.

3.

Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.

Berkelmans GFN, Gudbjörnsdottir S, Visseren FLJ, Wild SH, Franzen S, Chalmers J, Davis BR, Poulter NR, Spijkerman AM, Woodward M, Pressel SL, Gupta AK, van der Schouw YT, Svensson AM, van der Graaf Y, Read SH, Eliasson B, Dorresteijn JAN.

Eur Heart J. 2019 Jan 9. doi: 10.1093/eurheartj/ehy839. [Epub ahead of print]

PMID:
30629157
4.

Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART-REACH Model.

Kaasenbrood L, Bhatt DL, Dorresteijn JAN, Wilson PWF, D'Agostino RB Sr, Massaro JM, van der Graaf Y, Cramer MJM, Kappelle LJ, de Borst GJ, Steg PG, Visseren FLJ.

J Am Heart Assoc. 2018 Aug 21;7(16):e009217. doi: 10.1161/JAHA.118.009217.

5.

[Cholesterol-lowering drugs in the elderly. When to initiate, maintain or discontinue therapy?]

Kleipool EEF, Dorresteijn JAN, Visseren FLJ, Hollander M, Peters MJL, Muller M.

Ned Tijdschr Geneeskd. 2018 Oct 5;162. pii: D2658. Dutch.

PMID:
30358363
6.

Thyroid-stimulating hormone levels in the normal range and incident type 2 diabetes mellitus.

de Vries TI, Kappelle LJ, van der Graaf Y, de Valk HW, de Borst GJ, Nathoe HM, Visseren FLJ, Westerink J; SMART study group.

Acta Diabetol. 2019 Apr;56(4):431-440. doi: 10.1007/s00592-018-1231-y. Epub 2018 Sep 27.

PMID:
30259116
7.

The prediction of therapy-benefit for individual cardiovascular disease prevention: rationale, implications, and implementation.

Jaspers NEM, Ridker PM, Dorresteijn JAN, Visseren FLJ.

Curr Opin Lipidol. 2018 Dec;29(6):436-444. doi: 10.1097/MOL.0000000000000554.

PMID:
30234556
8.

Routinely measured hematological parameters and prediction of recurrent vascular events in patients with clinically manifest vascular disease.

Kofink D, Muller SA, Patel RS, Dorresteijn JAN, Berkelmans GFN, de Groot MCH, van Solinge WW, Haitjema S, Leiner T, Visseren FLJ, Hoefer IE, Asselbergs FW; SMART Study Group.

PLoS One. 2018 Sep 7;13(9):e0202682. doi: 10.1371/journal.pone.0202682. eCollection 2018.

9.

Prevalence of potential modifiable factors of hypertension in patients with difficult-to-control hypertension.

Van Der Sande NGC, Blankestijn PJ, Visseren FLJ, Beeftink MM, Voskuil M, Westerink J, Bots ML, Spiering W.

J Hypertens. 2019 Feb;37(2):398-405. doi: 10.1097/HJH.0000000000001885.

PMID:
30074565
10.

The relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease.

Schrover IM, van der Graaf Y, Spiering W, Visseren FL; SMART study group.

Eur J Prev Cardiol. 2018 Sep;25(14):1548-1557. doi: 10.1177/2047487318790722. Epub 2018 Jul 27.

11.

Combined use of polypill components in patients with type 2 diabetes mellitus.

Janssen VE, Visseren FL, de Boer A, Grobbee DE, Westerink J, van der Graaf Y, Lafeber M; SMART Study Group.

Eur J Prev Cardiol. 2018 Sep;25(14):1523-1531. doi: 10.1177/2047487318789494. Epub 2018 Jul 23.

PMID:
30033753
12.

Association between bone metabolism regulators and arterial stiffness in type 2 diabetes patients.

Sharif S, Bots ML, Schalkwijk C, Stehouwer CDA, Visseren FLJ, Westerink J; SMART study group.

Nutr Metab Cardiovasc Dis. 2018 Dec;28(12):1245-1252. doi: 10.1016/j.numecd.2018.06.004. Epub 2018 Jun 13.

PMID:
30017437
13.

Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy.

Hartgers ML, Besseling J, Stroes ES, Wittekoek J, Rutten JHW, de Graaf J, Visseren FLJ, Imholz BPM, Roeters van Lennep JE, Huijgen R, Kastelein JJP, Hovingh GK.

J Clin Lipidol. 2018 Jul - Aug;12(4):972-980.e1. doi: 10.1016/j.jacl.2018.04.002. Epub 2018 Apr 18.

PMID:
29934068
14.

Four ECG left ventricular hypertrophy criteria and the risk of cardiovascular events and mortality in patients with vascular disease.

van Kleef MEAM, Visseren FLJ, Vernooij JWP, Nathoe HM, Cramer MM, Bemelmans RHH, van der Graaf Y, Spiering W; SMART-study group.

J Hypertens. 2018 Sep;36(9):1865-1873. doi: 10.1097/HJH.0000000000001785.

PMID:
29878973
15.

Variation in minimum desired cardiovascular disease-free longevity benefit from statin and antihypertensive medications: a cross-sectional study of patient and primary care physician perspectives.

Jaspers NEM, Visseren FLJ, Numans ME, Smulders YM, van Loenen Martinet FA, van der Graaf Y, Dorresteijn JAN.

BMJ Open. 2018 May 26;8(5):e021309. doi: 10.1136/bmjopen-2017-021309.

16.

The prevalence of pseudoxanthoma elasticum: Revised estimations based on genotyping in a high vascular risk cohort.

Kranenburg G, Baas AF, de Jong PA, Asselbergs FW, Visseren FLJ, Spiering W; SMART study-group.

Eur J Med Genet. 2019 Feb;62(2):90-92. doi: 10.1016/j.ejmg.2018.05.020. Epub 2018 May 22.

PMID:
29800625
17.

Limited benefit of haemoglobin glycation index as risk factor for cardiovascular disease in type 2 diabetes patients.

Østergaard HB, Mandrup-Poulsen T, Berkelmans GFN, van der Graaf Y, Visseren FLJ, Westerink J; SMART Study Group.

Diabetes Metab. 2018 May 8. pii: S1262-3636(18)30083-1. doi: 10.1016/j.diabet.2018.04.006. [Epub ahead of print]

PMID:
29784563
18.

Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease.

Kaasenbrood L, Ray KK, Boekholdt SM, Smulders YM, LaRosa JC, Kastelein JJP, van der Graaf Y, Dorresteijn JAN, Visseren FLJ.

Heart. 2018 Oct;104(20):1699-1705. doi: 10.1136/heartjnl-2017-312510. Epub 2018 Apr 5.

19.

Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate.

Grams ME, Sang Y, Ballew SH, Carrero JJ, Djurdjev O, Heerspink HJL, Ho K, Ito S, Marks A, Naimark D, Nash DM, Navaneethan SD, Sarnak M, Stengel B, Visseren FLJ, Wang AY, Köttgen A, Levey AS, Woodward M, Eckardt KU, Hemmelgarn B, Coresh J.

Kidney Int. 2018 Jun;93(6):1442-1451. doi: 10.1016/j.kint.2018.01.009. Epub 2018 Mar 29. Erratum in: Kidney Int. 2018 Nov;94(5):1025-1026.

PMID:
29605094
20.

Etidronate for Prevention of Ectopic Mineralization in Patients With Pseudoxanthoma Elasticum.

Kranenburg G, de Jong PA, Bartstra JW, Lagerweij SJ, Lam MG, Ossewaarde-van Norel J, Risseeuw S, van Leeuwen R, Imhof SM, Verhaar HJ, de Vries JJ, Slart RHJA, Luurtsema G, den Harder AM, Visseren FLJ, Mali WP, Spiering W.

J Am Coll Cardiol. 2018 Mar 13;71(10):1117-1126. doi: 10.1016/j.jacc.2017.12.062.

PMID:
29519353
21.

Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes.

Koopal C, Visseren FLJ, Westerink J, van der Graaf Y, Ginsberg HN, Keech AC.

Diabetes Care. 2018 Jun;41(6):1244-1250. doi: 10.2337/dc17-0968. Epub 2018 Feb 22.

PMID:
29472432
22.

Prevalence of Subclinical Coronary Artery Disease Assessed by Coronary Computed Tomography Angiography in 45- to 55-Year-Old Women With a History of Preeclampsia.

Zoet GA, Benschop L, Boersma E, Budde RPJ, Fauser BCJM, van der Graaf Y, de Groot CJM, Maas AHEM, Roeters van Lennep JE, Steegers EAP, Visseren FL, van Rijn BB, Velthuis BK, Franx A; CREW Consortium.

Circulation. 2018 Feb 20;137(8):877-879. doi: 10.1161/CIRCULATIONAHA.117.032695. No abstract available.

PMID:
29459475
23.

Arterial stiffening and thickening in patients with pseudoxanthoma elasticum.

Kranenburg G, Visseren FLJ, de Borst GJ, de Jong PA, Spiering W; SMART studygroup.

Atherosclerosis. 2018 Mar;270:160-165. doi: 10.1016/j.atherosclerosis.2018.02.006. Epub 2018 Feb 9.

PMID:
29432933
24.

Random measurement error: Why worry? An example of cardiovascular risk factors.

Brakenhoff TB, van Smeden M, Visseren FLJ, Groenwold RHH.

PLoS One. 2018 Feb 9;13(2):e0192298. doi: 10.1371/journal.pone.0192298. eCollection 2018.

25.

Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease.

Stam-Slob MC, van der Graaf Y, de Boer A, Greving JP, Visseren FLJ.

Int J Cardiol. 2018 Feb 15;253:148-154. doi: 10.1016/j.ijcard.2017.10.080.

PMID:
29306457
26.

Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a cohort study.

Ocak G, Rookmaaker MB, Algra A, de Borst GJ, Doevendans PA, Kappelle LJ, Verhaar MC, Visseren FL; SMART Study Group.

J Thromb Haemost. 2018 Jan;16(1):65-73. doi: 10.1111/jth.13904. Epub 2017 Dec 20.

PMID:
29125709
27.

Cardiovascular and all-cause mortality in patients with intermittent claudication and critical limb ischaemia.

van Haelst STW, Koopman C, den Ruijter HM, Moll FL, Visseren FL, Vaartjes I, de Borst GJ.

Br J Surg. 2018 Feb;105(3):252-261. doi: 10.1002/bjs.10657. Epub 2017 Nov 8.

PMID:
29116654
28.

Identifying treatment response to antihypertensives in patients with obesity-related hypertension.

Schrover IM, Dorresteijn JAN, Smits JE, Danser AHJ, Visseren FLJ, Spiering W.

Clin Hypertens. 2017 Oct 24;23:20. doi: 10.1186/s40885-017-0077-x. eCollection 2017.

29.

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials.

de Jong M, van der Worp HB, van der Graaf Y, Visseren FLJ, Westerink J.

Cardiovasc Diabetol. 2017 Oct 16;16(1):134. doi: 10.1186/s12933-017-0617-4. Review.

30.

Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial.

Koopal C, Marais AD, Westerink J, van der Graaf Y, Visseren FLJ.

J Lipid Res. 2017 Nov;58(11):2180-2187. doi: 10.1194/jlr.M076901. Epub 2017 Sep 19.

31.

Prevalence and clinical characteristics of apparent therapy-resistant hypertension in patients with cardiovascular disease: a cross-sectional cohort study in secondary care.

de Beus E, van der Sande NGC, Bots ML, Spiering W, Voskuil M, Visseren FLJ, Blankestijn PJ.

BMJ Open. 2017 Sep 6;7(9):e016692. doi: 10.1136/bmjopen-2017-016692.

32.

Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes.

Engelen SE, van der Graaf Y, Stam-Slob MC, Grobbee DE, Cramer MJ, Kappelle LJ, de Borst GJ, Visseren FLJ, Westerink J; SMART study group.

Int J Cardiol. 2017 Dec 1;248:301-307. doi: 10.1016/j.ijcard.2017.07.081. Epub 2017 Jul 23.

PMID:
28802735
33.

Relation between adiposity and vascular events, malignancy and mortality in patients with stable cerebrovascular disease.

Jaspers NEM, Dorresteijn JAN, van der Graaf Y, Westerink J, Kappelle LJ, Nathoe HM, Algra A, Visseren FLJ.

Int J Obes (Lond). 2017 Dec;41(12):1775-1781. doi: 10.1038/ijo.2017.184. Epub 2017 Aug 4.

PMID:
28775374
34.

SPRINT trial: It's not just the blood pressure!

Berkelmans GF, Visseren FL, Jaspers NE, Spiering W, van der Graaf Y, Dorresteijn JA.

Eur J Prev Cardiol. 2017 Sep;24(14):1482-1484. doi: 10.1177/2047487317723213. Epub 2017 Jul 27.

PMID:
28749177
35.

Physical Activity and Characteristics of the Carotid Artery Wall in High-Risk Patients-The SMART (Second Manifestations of Arterial Disease) Study.

Boss HM, van der Graaf Y, Visseren FLJ, Van den Berg-Vos RM, Bots ML, de Borst GJ, Cramer MJ, Kappelle LJ, Geerlings MI; SMART Study Group.

J Am Heart Assoc. 2017 Jul 23;6(7). pii: e005143. doi: 10.1161/JAHA.116.005143.

36.

Decline in risk of recurrent cardiovascular events in the period 1996 to 2014 partly explained by better treatment of risk factors and less subclinical atherosclerosis.

Berkelmans GFN, van der Graaf Y, Dorresteijn JAN, de Borst GJ, Cramer MJ, Kappelle LJ, Westerink J, Visseren FLJ; SMART study group.

Int J Cardiol. 2018 Jan 15;251:96-102. doi: 10.1016/j.ijcard.2017.07.026. Epub 2017 Jul 14.

37.

Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data.

Matsushita K, Ballew SH, Coresh J, Arima H, Ärnlöv J, Cirillo M, Ebert N, Hiramoto JS, Kimm H, Shlipak MG, Visseren FLJ, Gansevoort RT, Kovesdy CP, Shalev V, Woodward M, Kronenberg F; Chronic Kidney Disease Prognosis Consortium.

Lancet Diabetes Endocrinol. 2017 Sep;5(9):718-728. doi: 10.1016/S2213-8587(17)30183-3. Epub 2017 Jul 14.

38.

Trends in comorbidity in patients hospitalised for cardiovascular disease.

Buddeke J, Bots ML, van Dis I, Liem A, Visseren FLJ, Vaartjes I.

Int J Cardiol. 2017 Dec 1;248:382-388. doi: 10.1016/j.ijcard.2017.06.106. Epub 2017 Jul 10.

39.

Inter-arm systolic blood pressure differences, relations with future vascular events and mortality in patients with and without manifest vascular disease.

Kranenburg G, Spiering W, de Jong PA, Kappelle LJ, de Borst GJ, Cramer MJ, Visseren FLJ, Aboyans V, Westerink J; SMART study group.

Int J Cardiol. 2017 Oct 1;244:271-276. doi: 10.1016/j.ijcard.2017.06.044. Epub 2017 Jun 13.

PMID:
28641891
40.

Risk Factors for Recurrent Cardiovascular Events Before Age 65 Years or Within 2.5 Years of a Recent First Cardiovascular Event.

van den Berg MJ, Westerink J, van der Graaf Y, Kappelle LJ, de Borst GJ, Cramer MM, Visseren FLJ; SMART study group.

Am J Cardiol. 2017 Jul 15;120(2):167-173. doi: 10.1016/j.amjcard.2017.04.002. Epub 2017 Apr 27.

PMID:
28532782
41.

[Syncope; suspect pulmonary embolism, especially in the elderly].

Opstelten W, Visseren FLJ.

Ned Tijdschr Geneeskd. 2017;161:D1365. Dutch.

PMID:
28488555
42.

Relation between Kidney Length and Cardiovascular and Renal Risk in High-Risk Patients.

van der Sande NGC, Visseren FLJ, van der Graaf Y, Nathoe HM, de Borst GJ, Leiner T, Blankestijn PJ; SMART Study Group.

Clin J Am Soc Nephrol. 2017 Jun 7;12(6):921-928. doi: 10.2215/CJN.08990816. Epub 2017 May 9.

43.

Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.

Lafeber M, Spiering W, Visseren FL, Grobbee DE, Bots ML, Stanton A, Patel A, Prabhakaran D, Webster R, Thom S, Rodgers A; UMPIRE investigators.

Eur J Prev Cardiol. 2017 Jun;24(9):951-961. doi: 10.1177/2047487317695616. Epub 2017 Mar 8.

PMID:
28436727
44.

Autosomal dominant familial dysbetalipoproteinemia: A pathophysiological framework and practical approach to diagnosis and therapy.

Koopal C, Marais AD, Westerink J, Visseren FL.

J Clin Lipidol. 2017 Jan - Feb;11(1):12-23.e1. doi: 10.1016/j.jacl.2016.10.001. Epub 2016 Oct 13. Review.

PMID:
28391878
45.

Safety of Temporary Discontinuation of Antihypertensive Medication in Patients With Difficult-to-Control Hypertension.

Beeftink MM, van der Sande NG, Bots ML, Doevendans PA, Blankestijn PJ, Visseren FL, Voskuil M, Spiering W.

Hypertension. 2017 May;69(5):927-932. doi: 10.1161/HYPERTENSIONAHA.116.08793. Epub 2017 Apr 3.

PMID:
28373591
46.

Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria.

van den Berg MJ, Bhatt DL, Kappelle LJ, de Borst GJ, Cramer MJ, van der Graaf Y, Steg PG, Visseren FLJ; SMART study group; REACH Registry investigators.

Eur Heart J. 2017 Nov 14;38(43):3211-3218. doi: 10.1093/eurheartj/ehx102.

PMID:
28369481
47.

Response by Kaasenbrood et al to Letter Regarding Article, "Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population".

Kaasenbrood L, van der Graaf Y, Visseren FL.

Circulation. 2017 Mar 28;135(13):e820-e821. doi: 10.1161/CIRCULATIONAHA.117.027317. No abstract available.

PMID:
28348097
48.

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.

Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, Hall T, Troquay RP, Turner T, Visseren FL, Wijngaard P, Wright RS, Kastelein JJ.

N Engl J Med. 2017 Apr 13;376(15):1430-1440. doi: 10.1056/NEJMoa1615758. Epub 2017 Mar 17.

49.

Relation of Epicardial Adipose Tissue Radiodensity to Coronary Artery Calcium on Cardiac Computed Tomography in Patients at High Risk for Cardiovascular Disease.

Franssens BT, Nathoe HM, Visseren FL, van der Graaf Y, Leiner T; SMART Study Group.

Am J Cardiol. 2017 May 1;119(9):1359-1365. doi: 10.1016/j.amjcard.2017.01.031. Epub 2017 Feb 11.

PMID:
28279438
50.

Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients.

Stam-Slob MC, van der Graaf Y, Greving JP, Dorresteijn JA, Visseren FL.

J Am Heart Assoc. 2017 Feb 18;6(2). pii: e004648. doi: 10.1161/JAHA.116.004648.

Supplemental Content

Loading ...
Support Center